HomeCompareNMTR vs PEP

NMTR vs PEP: Dividend Comparison 2026

NMTR yields 2770.08% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTR wins by $212938372920.77M in total portfolio value
10 years
NMTR
NMTR
● Live price
2770.08%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212938372920.91M
Annual income
$198,819,380,806,317,020.00
Full NMTR calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — NMTR vs PEP

📍 NMTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTRPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTR + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMTR pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTR
Annual income on $10K today (after 15% tax)
$235,457.06/yr
After 10yr DRIP, annual income (after tax)
$168,996,473,685,369,470.00/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, NMTR beats the other by $168,996,473,685,316,860.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTR + PEP for your $10,000?

NMTR: 50%PEP: 50%
100% PEP50/50100% NMTR
Portfolio after 10yr
$106469186460.53M
Annual income
$99,409,690,403,189,460.00/yr
Blended yield
93.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

NMTR
No analyst data
Altman Z
-49.9
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTR buys
0
PEP buys
0
No recent congressional trades found for NMTR or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTRPEP
Forward yield2770.08%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$212938372920.91M$141.9K
Annual income after 10y$198,819,380,806,317,020.00$61,875.67
Total dividends collected$211957883813.74M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NMTR vs PEP ($10,000, DRIP)

YearNMTR PortfolioNMTR Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$287,708$277,008.31$10,849$509.42+$276.9KNMTR
2$7,756,221$7,448,373.17$11,969$750.47+$7.74MNMTR
3$195,960,759$187,661,602.67$13,500$1,124.14+$195.95MNMTR
4$4,640,768,087$4,431,090,074.46$15,680$1,721.66+$4640.75MNMTR
5$103,038,191,206$98,072,569,353.09$18,929$2,715.34+$103038.17MNMTR
6$2,145,287,049,877$2,035,036,185,286.86$24,023$4,450.80+$2145287.03MNMTR
7$41,893,666,105,695$39,598,208,962,326.13$32,510$7,669.92+$41893666.07MNMTR
8$767,520,675,750,287$722,694,453,017,193.00$47,709$14,093.60+$767520675.70MNMTR
9$13,195,319,733,262,706$12,374,072,610,209,900.00$77,415$28,083.48+$13195319733.19MNMTR
10$212,938,372,920,908,130$198,819,380,806,317,020.00$141,922$61,875.67+$212938372920.77MNMTR

NMTR vs PEP: Complete Analysis 2026

NMTRStock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Full NMTR Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this NMTR vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTR vs SCHDNMTR vs JEPINMTR vs ONMTR vs KONMTR vs MAINNMTR vs MONMTR vs PMNMTR vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.